The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...

Coming back to the first-quarter results, sales of most of its products, like Prolia, Xgeva, Repatha, Blincyto and Evenity, beat estimates. Fourteen products, including Repatha, Blincyto ...

More information: Donghee Han et al, Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography, JACC: Cardiovascular Imaging (2025 ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones ...

Amgen Inc. operates as a manufacturer, developer, discoverer, and deliverer of human therapeutics. Its key product candidates are Enbrel, XGEVA, Otezla, KYPROLIS ...

Drugs such as Repatha, Tezspire, and Blincyto, an immunology drug for leukemia, continue to grow rapidly. The company also recently launched Imdelltra, the first bispecific T-cell engager for ...

“I already exercise, take a statin, and eat kale,” he tells the white-coated doctor. “Take Repatha,” the doctor advises. Can I stop the kale? The drug follies go on endlessly — pharma ...

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology ...

Key growth drivers (not an exhaustive list) include Tezspire, an asthma medication; Repatha, which treats high cholesterol; and blood-cancer medicine Blincyto. Like every drugmaker, Amgen will ...